BCR-ABL-IN-9 (Compound B1) is a BCR-ABL inhibitor that achieves sustained BCR-ABL suppression by forming stable covalent bonds with the ABL kinase. BCR-ABL-IN-9 is also effective in inhibiting the activity of the ABL kinase (IC50 = 1.2 nM). BCR-ABL-IN-9 possesses anticancer activity[1].
Molekulargewicht:
388.42
Formel:
C22H20N4O3
Target-Kategorie:
Bcr-Abl
Anwendungsbeschreibung:
MCE Product type: Reference compound1
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
